CooperVision to Launch MyDay® MiSight® 1 Day Soft Contact Lenses for Myopia Control in the UK

CooperVision to Launch MyDay® MiSight® 1 Day Contact Lenses

CooperVision recently announced the upcoming introduction of its MyDay® MiSight® 1 Day soft contact lenses aimed at myopia control, set to launch in the United Kingdom and selected European and adjacent markets. This launch signifies a pivotal expansion in CooperVision's evidence-based portfolio for managing myopia.

Understanding Myopia and Its Impact

Myopia, commonly referred to as nearsightedness, is a condition affecting millions worldwide, and current projections suggest that one in two children born today could develop myopia by the time they turn 20. This condition can significantly impair a child's quality of life, affecting their participation in educational, sporting, and social activities. Notably, myopia can progress rapidly, especially in younger children, making early intervention crucial.

Debbie Olive, CooperVision's Commercial Director, emphasized the company's unwavering commitment to combat myopia both scientifically and commercially. The new MyDay® MiSight® 1 Day lenses incorporate advanced silicone hydrogel material which had previously been used in the MyDay® lenses, alongside the proven MiSight® 1 Day ActivControl® technology.

Technological Innovations for Effective Control

CooperVision's ActivControl® technology has demonstrated an approximate 50% reduction in myopia progression, supported by the longest clinical study involving soft contact lenses for children. Currently, hundreds of thousands of children worldwide are benefitting from lenses equipped with this innovative technology.

The design of the MyDay® MiSight® lenses includes vision correction zones and treatment zones, ensuring clear vision while simultaneously aiding in the control of myopia's progression. Jennifer Lambert, Vice President of Myopia Management and Corneal Care, noted that this innovation provides continuous myopia control, allowing children to benefit from the treatment throughout the day simply by wearing the lenses.

A New Approach to Myopia Treatment

Distinctively, the soft MyDay® MiSight® 1 Day lenses are crafted to facilitate a seamless transition from myopia management to the use of adult lenses, ensuring sustained ocular health. The product will be available in various parameters when it hits the UK and selected European markets, with spherical power ranging from -0.25 to -10.00.

The Future of Vision Care

CooperVision, a division of CooperCompanies, is committed to addressing complex vision challenges, such as astigmatism, presbyopia, and pediatric myopia. The company’s comprehensive range of spherical, toric, and multifocal products is designed to deliver innovative solutions tailored to diverse vision needs. Their products, all unique in specification, focus on providing tangible benefits for users and their eye care professionals.

In conclusion, CooperVision's MyDay® MiSight® 1 Day lenses represent a significant advancement in the fight against myopia. With their launch, thousands of children could experience improved vision and an enhanced quality of life. For more information about this groundbreaking product and CooperVision's evidence-based myopia management portfolio, visit CooperVision.